HALISTER: Biogen FY Rev. View Trails Est.

Biogen FY Rev. View Trails Est.

(Bloomberg) -- Biogen sees FY rev. $11.1b to $11.4b, est. $12.1b
  • 4Q rev. $2.87b, est. $2.94b (range $2.75b-$3.07b)
  • 4Q adj. EPS $5.04, est. $4.96 (range $4.43-$5.50)
  • 4Q Tecfidera rev. $1.00b, est. $1.02b (Bloomberg data)
    • 4Q Tysabri rev. $473.9m, est. $506.9m
    • 4Q Alprolix rev. $93.2m, est. $90.5m (average of 12)
    • 4Q Eloctate rev. $149.0m, est. $138.6m (average of 12)
  • Sees 2017 adj. EPS $20.45 - $21.25
  • Sees 2017 adj. EPS $20.45 & $21.25
  • Ignore: Biogen CEO, Forward Pharma Pact Previously Reported
  • Sees 2017 rev. $11.1b to $11.4b, est. $12.1b
  • Sees 2017 rev. $11.1b to $11.4b
  • Sees 2017 adj. EPS $20.45 - $21.25, est. $21.03
NOTE:
  • 19 buys, 9 holds, 0 sells before today
  • Call 8am (NY time), (877)-650-1145 pw 45044921
Statement
Alert: HALISTER
Source: BFW (Bloomberg First Word)

Tickers
BIIB US (Biogen Inc)

To de-activate this alert, click here

UUID: 7947283